What is the primary purpose of the debt offerings mentioned in this filing?

The primary purpose of these debt offerings by CH JVCo subsidiaries is to raise capital to fund a portion of a cash dividend intended for GSK and Pfizer, reflecting their respective ownership interests in the joint venture prior to the planned demerger.

What is Pfizer's direct financial exposure to these debt offerings?

Pfizer's direct financial exposure is limited. Pfizer and its subsidiaries are not the issuers or guarantors of these notes. However, Pfizer has agreed to indemnify GSK for 32% of any amounts GSK may be required to pay under its guarantee of these notes, which directly correlates to Pfizer's 32% ownership stake in CH JVCo.

Under what conditions would these notes be redeemed early?

The notes will be redeemed at 101% of their principal amount if the planned demerger of CH JVCo is not completed by the first anniversary of the notes' issue date, or if GSK announces it no longer intends to pursue the demerger.

How does this filing relate to the planned demerger of the consumer healthcare business?

This filing is directly related to the demerger as the debt offerings were undertaken by subsidiaries of CH JVCo in anticipation of GSK's planned demerger. The proceeds are intended to facilitate a dividend distribution related to the ownership structure before the demerger is finalized, and the guarantees and indemnities are structured around the progression and completion of this demerger.

PFE 8-K SEC Disclosure — Mar 29, 2022

Summary

This 8-K filing by Pfizer Inc. (PFE) details significant financing activities related to the planned demerger of the GlaxoSmithKline Consumer Healthcare joint venture (CH JVCo). While Pfizer retains a 32% ownership stake in CH JVCo, the report primarily concerns the debt offerings by subsidiaries of CH JVCo, totaling billions of dollars across various currencies (USD, GBP, EUR) and maturities. These offerings are intended to fund a portion of a cash dividend to be distributed to GSK and Pfizer, reflecting their respective ownership interests prior to the demerger. The filing also clarifies the conditions under which these notes would be redeemed and outlines guarantees and indemnification agreements between GSK and Pfizer related to these debt instruments.

Key Highlights

1Subsidiaries of GlaxoSmithKline Consumer Healthcare Holdings (No. 2) Limited (CH JVCo) completed multiple senior notes offerings totaling billions in USD, GBP, and EUR.
2The debt offerings include fixed-rate senior notes with maturities ranging from 2024 to 2052 in USD, 2025 to 2038 in GBP, and 2026 to 2034 in EUR.
3Proceeds from these note offerings are intended to fund a portion of a cash dividend to GSK and Pfizer, based on their ownership stakes in CH JVCo.
4The notes are guaranteed by GSK until a specific 'Guarantee Assumption Date' related to the demerger.
5Pfizer has agreed to indemnify GSK for 32% of any amounts paid under the GSK Guarantee, reflecting Pfizer's ownership interest in CH JVCo.
6The notes will be redeemed at 101% of their principal amount if the demerger is not completed within one year of the issue date or if GSK withdraws its intention to pursue the demerger.
7Pfizer and its subsidiaries are neither issuers nor guarantors of any of the notes mentioned in the filing.

PFIZER INC 8-K Report, Corporate Update (Mar 29, 2022)

Summary

Key Highlights

Frequently Asked Questions